Web stats for Pomalyst - pomalyst.com

2.50 Rating by ClearWebStats
pomalyst.com is 1 decade 3 years 4 months old. This website has a #5,414,489 rank in global traffic. It has a com as an domain extension. This website has a Google PageRank of 5 out of 10. The DNS for Pomalyst is hosted at 207.99.94.5. While no active threats were reported recently by users, pomalyst.com is SAFE to browse.
Get Custom Widget

Traffic Report of Pomalyst

Daily Unique Visitors: 89
Daily Pageviews: 178

Estimated Valuation

Income Per Day: $ 1.00
Estimated Worth: $ 240.00

Search Engine Indexes

Google Indexed Pages: Not Applicable
Yahoo Indexed Pages: Not Applicable
Bing Indexed Pages: Not Applicable

Search Engine Backlinks

Google Backlinks: Not Applicable
Bing Backlinks: Not Applicable

Safety Information

Google Safe Browsing: No Risk Issues
Siteadvisor Rating: Not Applicable
WOT Trustworthiness: Not Applicable
WOT Privacy: Not Applicable
WOT Child Safety: Not Applicable

Website Ranks & Scores

Google Pagerank: View pomalyst.com Pagerank
Alexa Rank: 5,414,489
Domain Authority: Not Applicable
Google Pagerank
PR 5 out of 10
PageSpeed Score
Score: 58on 100
Siteadvisor Rating
View pomalyst.com site advisor rating Not Applicable

Where is pomalyst.com server located?

Hosted IP Address:

207.99.94.5 View other site hosted with pomalyst.com

Hosted Country:

pomalyst.com hosted country US pomalyst.com hosted country

Location Latitude:

40.7357

Location Longitude:

-74.1724

Social Engagement

Facebook Shares: Not Applicable
Facebook Likes: Not Applicable
Facebook Comments: Not Applicable

Page Resources Breakdown

View pomalyst.com HTML resources

Homepage Links Analysis

View pomalyst.com homepage link analysis

Pomalyst Multiple Myeloma Treatment Cancer Treatment Options

Information on a prescription medicine used to treat people with multiple myeloma who have received at least two prior medicines to treat multiple myeloma Important Safety Information WARNING: EMBRYO-FETAL TOXICITY and VENOUS THROMBOEMBOLISM Embryo-Fetal Toxicity POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting POMALYST treatment Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping POMALYST treatment POMALYST is only available through a restricted distribution program called POMALYST REMSTM. Venous Thromboembolism Deep venous thrombosis (DVT) and pulmonary embolism (PE) occur in patients with multiple myeloma treated with POMALYST. Prophylactic anti-thrombotic measures were employed in the clinical trial. Consider prophylactic measures after assessing an individual patient’s underlying risk factors CONTRAINDICATIONS: Pregnancy POMALYST can cause fetal harm and is contraindicated in females who are pregnant. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus Pomalidomide is a thalidomide analogue and is teratogenic in both rats and rabbits when administered during the period of organogenesis WARNINGS AND PRECAUTIONS Embryo-Fetal Toxicity Females of Reproductive Potential: Must avoid pregnancy while taking POMALYST and for at least 4 weeks after completing therapy. Must commit either to abstain continuously from heterosexual sexual intercourse or to use 2 methods of reliable birth control, beginning 4 weeks prior to initiating treatment with POMALYST, during therapy, during dose interruptions, and continuing for 4 weeks following discontinuation of POMALYST therapy. Must obtain 2 negative pregnancy tests prior to initiating therapy Males: Pomalidomide is present in the semen of patients receiving the drug. Males must always use a latex or synthetic condom during any sexual contact with females of reproductive potential while taking POMALYST and for up to 28 days after discontinuing POMALYST, even if they have undergone a successful vasectomy. Males must not donate sperm Blood Donation: Patients must not donate blood during treatment with POMALYST and for 1 month following discontinuation of POMALYST therapy because the blood might be given to a pregnant female patient whose fetus must not be exposed to POMALYST POMALYST REMS Program Because of the embryo-fetal risk, POMALYST is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called “POMALYST REMS.” Prescribers and pharmacies must be certified with the program; patients must sign an agreement form and comply with the requirements. Further information about the POMALYST REMS program is available at www.CelgeneRiskManagement.com or by telephone at 1-888-423-5436. Venous Thromboembolism: Patients receiving POMALYST have developed venous thromboembolic events reported as serious adverse reactions. In the trial, all patients were required to receive prophylaxis or antithrombotic treatment. The rate of DVT or PE was 3%. Consider anticoagulation prophylaxis after an assessment of each patient’s underlying risk factors. Hematologic Toxicity: Neutropenia of any grade was reported in 50% of patients and was the most frequently reported Grade 3/4 adverse reaction, followed by anemia and thrombocytopenia. Monitor patients for hematologic toxicities, especially neutropenia, with complete blood counts weekly for the first 8 weeks and monthly thereafter. Treatment is continued or modified for Grade 3 or 4 hematologic toxicities based upon clinical and laboratory findings. Dosing interruptions and/or modifications are recommended to manage neutropenia and thrombocytopenia. Hypersensitivity Reactions: Patients with a prior history of serious hypersensitivity associated with thalidomide or lenalidomide were excluded from studies and may be at higher risk of hypersensitivity. Dizziness and Confusional State: 18% of patients experienced dizziness and 12% of patients experienced a confusional state; 1% of patients experienced Grade 3/4 dizziness, and 3% of patients experienced Grade 3/4 confusional state. Instruct patients to avoid situations where dizziness or confusional state may be a problem and not to take other medications that may cause dizziness or confusional state without adequate medical advice. Neuropathy: 18% of patients experienced neuropathy (approximately 9% peripheral neuropathy). There were no cases of Grade 3 or higher neuropathy adverse reactions reported. Risk of Second Primary Malignancies: Cases of acute myelogenous leukemia have been reported in patients receiving POMALYST as an investigational therapy outside of multiple myeloma. Tumor Lysis Syndrome: Tumor lysis syndrome (TLS) may occur in patients treated with pomalidomide. Patients at risk for TLS are those with high tumor burden prior to treatment. These patients should be monitored closely and appropriate precautions taken. ADVERSE REACTIONS In the clinical trial of 219 patients who received POMALYST alone (n=107) or POMALYST + low-dose dexamethasone (low-dose dex) (n=112), all patients had at least one treatment-emergent adverse reaction. In the POMALYST alone versus POMALYST + low-dose dex arms, the most common adverse reactions (≥30%), respectively, included fatigue and asthenia (55%, 63%), neutropenia (52%, 47%), anemia (38%, 39%), constipation (36%, 35%), nausea (36%, 22%), diarrhea (34%, 33%), dyspnea (34%, 45%), upper respiratory tract infection (32%, 25%), back pain (32%, 30%), and pyrexia (19%, 30%) 90% of patients treated with POMALYST alone and 88% of patients treated with POMALYST + low-dose dex had at least one treatment-emergent NCI CTC Grade 3 or 4 adverse reaction In the POMALYST alone versus POMALYST + low-dose dex arms, the most common Grade 3/4 adverse reactions (≥15%), respectively, included neutropenia (47%, 38%), anemia (22%, 21%), thrombocytopenia (22%, 19%), and pneumonia (16%, 23%). For other Grade 3 or 4 toxicities besides neutropenia and thrombocytopenia, hold treatment and restart treatment at 1 mg less than the previous dose when toxicity has resolved to less than or equal to Grade 2 at the physician’s discretion 67% of patients treated with POMALYST and 62% of patients treated with POMALYST + low-dose dex had at least one treatment-emergent serious adverse reaction In the POMALYST alone versus POMALYST + low-dose dex arms, the most common serious adverse reactions (≥5%), respectively, were pneumonia (14%, 19%), renal failure (8%, 6%), dyspnea (5%, 6%), sepsis (6%, 3%), pyrexia (3%, 5%), dehydration (5%, 3%), hypercalcemia (5%, 2%), urinary tract infection (0%, 5%), and febrile neutropenia (5%, 1%) DRUG INTERACTIONS Pomalidomide is primarily metabolized by CYP1A2 and CYP3A. Pomalidomide is also a substrate for P-glycoprotein (P-gp). Avoid the use of strong CYP1A2 inhibitors. If medically necessary to co-administer strong inhibitors of CYP1A2 in the presence of strong inhibitors of CYP3A4 and P-gp, reduce POMALYST dose by 50%. Cigarette smoking may reduce pomalidomide exposure due to CYP1A2 induction. Patients should be advised that smoking may reduce the efficacy of pomalidomide. USE IN SPECIFIC POPULATIONS Pregnancy: If pregnancy does occur during treatment, immediately discontinue the drug and refer patient to an obstetrician/gynecologist experienced in reproductive toxicity for further evaluation and counseling. Report any suspected fetal exposure to POMALYST to the FDA via the MedWatch program at 1-800-332-1088 and also to Celgene Corporation at 1-888-423-5436. Nursing Mothers: It is not known if pomalidomide is excreted in human milk. Pomalidomide was excreted in the milk of lactating rats. Because many drugs are excreted in human milk and because of the potential for adverse reactions in nursing infants from POMALYST, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Pediatric Use: Safety and effectiveness of POMALYST in patients under the age of 18 have not been established. Geriatric Use: No dosage adjustment is required for POMALYST based on age. Patients greater than or equal to 65 years of age were more likely than patients less than or equal to 65 years of age to experience pneumonia. Renal and Hepatic Impairment: Pomalidomide is metabolized in the liver. Pomalidomide and its metabolites are primarily excreted by the kidneys. The influence of renal and hepatic impairment on the safety, efficacy, and pharmacokinetics of pomalidomide has not been evaluated. Avoid POMALYST in patients with a serum creatinine >3.0 mg/dL. Avoid POMALYST in patients with serum bilirubin >2.0 mg/dL and AST/ALT >3.0 x ULN. Please see full Prescribing Information, including Boxed WARNINGS, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and ADVERSE REACTIONS.

Similar Domain Names

These are similar domain names that may be used for typosquatting or phishing attacks. Always verify the URL before entering any sensitive information.

  • pomalyst.co
  • pomalyst.cm
  • pomalyst.con
  • pomalyst.net
  • pomalyst.org
  • ppomalyst.com
  • poomalyst.com
  • pommalyst.com
  • pomaalyst.com
  • pomallyst.com
  • pomalyyst.com
  • pomalysst.com
  • pomalystt.com
  • omalyst.com
  • pmalyst.com

Website Inpage Analysis

H1 Headings: 29 H2 Headings: 7
H3 Headings: Not Applicable H4 Headings: 1
H5 Headings: Not Applicable H6 Headings: Not Applicable
Total IFRAMEs: Not Applicable Total Images: 57
Google Adsense: Not Applicable Google Analytics: UA-46839275-1

Websites Hosted on Same IP (i.e. 207.99.94.5)

Revlimid Gateway Page » Revlimid

pomalyst.com favicon - revlimid.com

View pomalyst.com Pagerank   pomalyst.com alexa rank 2,628,429   pomalyst.com website value $ 240.00

HTTP Header Analysis

Http-Version: 1.1
Status-Code: 200
Status: 200 OK
Date: Wed, 29 Oct 2014 21:23:04 GMT
Server: Apache/2.2.15 (Red Hat)
X-Powered-By: PHP/5.3.3
X-Pingback: http://www.pomalyst.com/xmlrpc.php
Link: ; rel=shortlink
Transfer-Encoding: chunked
Content-Type: text/html; charset=UTF-8

Domain Information for pomalyst.com

Domain Registrar: CSC CORPORATE DOMAINS, INC. pomalyst.com registrar info
Registration Date: 2012-09-24 1 decade 3 years 4 months ago
Last Modified: 2014-09-21 1 decade 1 year 5 months ago
Expiration Date: 2015-09-24 1 decade 5 months 19 hours ago
Domain Status: clientTransferProhibited

Domain Nameserver Information

Host IP Address Country
dns1.cscdns.net pomalyst.com name server information 156.154.130.100 pomalyst.com server is located in United States United States
dns2.cscdns.net pomalyst.com name server information 156.154.131.100 pomalyst.com server is located in United States United States

DNS Record Analysis

Host Type TTL Extra
pomalyst.com A 299 IP:207.99.94.5
pomalyst.com NS 14399 Target:dns1.cscdns.net
pomalyst.com NS 14399 Target:dns2.cscdns.net
pomalyst.com SOA 14399 MNAME:dns1.cscdns.net
RNAME:hostmaster.cscdns.net
Serial:2013013105
Refresh:28800
Retry:7200
Expire:604800
Minimum TTL:14400
pomalyst.com MX 14399 Priority:10
Target:custmx.cscdns.net

Similarly Ranked Websites to Pomalyst

Find Used Cars, Find New Cars, Find Great Deals | CarAutoPlex.com

pomalyst.com favicon - carautoplex.com

Use CarAutoPlex.com to search millions of new and used car listings. Find the right vehicle in a matter of seconds, without all the hassle.

View pomalyst.com Pagerank   Alexa rank for pomalyst.com 5,414,499   website value of pomalyst.com $ 240.00

Virtual Medical Books

pomalyst.com favicon - virtualmedicalbooks.com

View pomalyst.com Pagerank   Alexa rank for pomalyst.com 5,414,527   website value of pomalyst.com $ 240.00

Karina Smirnoff

pomalyst.com favicon - karinasmirnoff.com

View pomalyst.com Pagerank   Alexa rank for pomalyst.com 5,414,527   website value of pomalyst.com $ 240.00

Diétás termékek - Diétás ételek - Diétás webshop

pomalyst.com favicon - diabetikuswebshop.hu

Diétás termékek a sikeres diéta betartásához! A Diabetikus Webshop kínálatában rengeteg diétás terméket megtalálsz, kedvező szállítási díjakkal. Katt ide->

View pomalyst.com Pagerank   Alexa rank for pomalyst.com 5,414,544   website value of pomalyst.com $ 240.00

SFO Shuttle Bus

pomalyst.com favicon - sfoshuttle.net

View pomalyst.com Pagerank   Alexa rank for pomalyst.com 5,414,545   website value of pomalyst.com $ 240.00
Copyright © 2026 ClearWebStats.com, All Rights Reserved.
All brand names, logos, and trademarks appearing on this site are the property of their respective owners. ClearWebStats is an independent service that provides publicly available website statistics and is not affiliated with, endorsed by, or sponsored by any brand or website featured on this platform.